Lacosamide is a new-generation antiepileptic for partial epilepsy.
Also known as: vimpat
DailyMed/FDA — Vimpat; EMC-UK — Lacosamide
DailyMed/FDA — Vimpat; EMC-UK
Antiepileptic + CYP2C19 inhibitor: fluconazole may slightly increase lacosamide.
Lacosamide is partially metabolised by CYP2C19. Fluconazole inhibits CYP2C19, increasing levels.
Signs of toxicity (dizziness, diplopia).
Monitor adverse effects.
DailyMed/FDA; EMC-EMC PT
No documented food or drink interactions.
No documented disease interactions.
Limited pregnancy data. Animal studies do not show significant teratogenicity.
Insufficient data. Use only if benefit justifies risk.
Insufficient data on excretion in breast milk.
Insufficient data.
DailyMed/FDA — Vimpat; EMC-UK
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Selective antiepileptic activity via potentiation of slow Na⁺ channel inactivation.
Selectively potentiates slow inactivation of voltage-gated Na⁺ channels (different from phenytoin/carbamazepine which potentiate fast inactivation). Result: fewer neuropathic adverse effects.
Rapid and complete oral absorption. Bioavailability: 100%. Peak: 1-4 h.
Metabolised by CYP3A4 (30%) and CYP2C19 (15%). 50% excreted unchanged renally. Weakly inhibits CYP2C19.
13 h.
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
